Company Directory / research
PrivateFor profitresearchParis, France
ENTEROME
Enterome is a clinical-stage company developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases.
- Founded
- 2012 14 years ago
- Staff
- 51-100 band, as listed
- Followers
- - on LinkedIn
- Funding
- $176M as listed, currency not stated
Set against six million companies
Size
51-100 people: larger than 75% of companies with a size listed
Age
14 years old.
Reach
Website ranked #5,267,369 in the world for traffic, about 1k visits a month.
What it does
BiopharmaBiotechnologyHealth CareLife Science
Funding, as listed
$176M currency not stated
- Rounds9
- LatestSeries unknown, Oct 2023
- Investors12, 4 leading
What the source datasets report. We have not watched these rounds ourselves.
Every detail we hold
Everything the source datasets list about ENTEROME, field by field. Contact details are held but never shown.
The company
- Name
- ENTEROME
- Type
- For profit
- Status
- Private
- Founded
- 2012
- Founders
- Pierre Belichard, Stanislav Dusko EHRLICH
- Industry
- research
- Categories
- Biopharma, Biotechnology, Health Care, Life Science
Where
- City
- Paris
- Country
- France
- Markets
- European Union (EU), Europe, Middle East, and Africa (EMEA)
Size and reach
- Staff band
- 51-100
- Web traffic rank
- #5,267,369
- Monthly web visits
- 1,462
Funding, as listed
- Total
- 175,800,000 (currency not stated)
- Rounds
- 9
- Latest round
- Series unknown
- Latest round date
- Oct 2023
- Investors
- 12
- Lead investors
- 4
- Listing status
- private
About this record
- Sources
- Crunchbase
- Last imported
- Sept 2026
Growth, as the source summarises it
ENTEROME may be growing as evidenced by its involvement in a codevelopment agreement with Nestle Health, which suggests an expansion of its business partnerships. Additionally, the company is listed among leading companies in the marginal zone lymphoma market, indicating its active role and potential growth in this therapeutic area. Furthermore, ENTEROME is conducting a phase 2 clinical trial for a unique vaccine, demonstrating progress in its product pipeline and commitment to advancing its research and development.
Summaries written by the source dataset, not by us, and not checked.
Companies like it
research in France.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 88,142 companies in France and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.